Reckitt Records Impairment Charge For Biofreeze
Executive Summary
Reckitt recorded a £152m impairment charge for Biofreeze in 2022 after the topical pain relief brand underperformed in the first half of the year. Despite issues for Biofreeze, Reckitt's Health business as a whole had a strong showing over the 12 months, with sales jumping by 19%.
You may also be interested in...
Euro Q4 Consumer Health Earnings Preview: Sanofi, Bayer, Haleon, Reckitt
Major Europe-based consumer health players Sanofi, Bayer, Haleon and Reckitt all feature in this sales and earnings preview, which highlights what to look out for and potential talking points as these four companies report Q4 and full-year results over the coming weeks.
Haleon’s ‘#1 Doctor Recommended’ Voltaren Claim Challenged By RB Clears NAD Review With Caveat
NAD says in advertising without references to arthritis, Haleon should ensure claim Reckitt challenged “clearly and conspicuously discloses that Voltaren is approved for the treatment of arthritis pain.” Haleon supports “#1 Doctor Recommended” and “#1 Topical Pain Reliever Globally” claims.
Reckitt Claims Market Leading OTC Growth As Q1 Sales Rise Double Digits
Reckitt's OTC sales jumped 30% in Q1, helped by a strong cold & flu season, with the company enjoying market leading growth, according to interim CEO Nicandro Durante.